Advances and perspectives in prostate cancer biomarker discovery in the last 5 years through tissue and urine metabolomics
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10284/9975 |
Resumo: | Prostate cancer (PCa) is the second most diagnosed cancer in men worldwide. For its screening, serum prostate specific antigen (PSA) test has been largely performed over the past decade, despite its lack of accuracy and inability to distinguish indolent from aggressive disease. Metabolomics has been widely applied in cancer biomarker discovery due to the well-known metabolic reprogramming characteristic of cancer cells. Most of the metabolomic studies have reported alterations in urine of PCa patients due its noninvasive collection, but the analysis of prostate tissue metabolome is an ideal approach to disclose specific modifications in PCa development. This review aims to summarize and discuss the most recent findings from tissue and urine metabolomic studies applied to PCa biomarker discovery. Eighteen metabolites were found consistently altered in PCa tissue among different studies, including alanine, arginine, uracil, glutamate, fumarate, and citrate. Urine metabolomic studies also showed consistency in the dysregulation of 15 metabolites and, interestingly, alterations in the levels of valine, taurine, leucine and citrate were found in common between urine and tissue studies. These findings unveil that the impact of PCa development in human metabolome may offer a promising strategy to find novel biomarkers for PCa diagnosis. |
id |
RCAP_b23827b123e196d3bf4665b224217fb6 |
---|---|
oai_identifier_str |
oai:bdigital.ufp.pt:10284/9975 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Advances and perspectives in prostate cancer biomarker discovery in the last 5 years through tissue and urine metabolomicsMetabolomicsVolatilomicsLipidomicsProstate cancerBiomarkersMetabolic pathwaysProstate cancer (PCa) is the second most diagnosed cancer in men worldwide. For its screening, serum prostate specific antigen (PSA) test has been largely performed over the past decade, despite its lack of accuracy and inability to distinguish indolent from aggressive disease. Metabolomics has been widely applied in cancer biomarker discovery due to the well-known metabolic reprogramming characteristic of cancer cells. Most of the metabolomic studies have reported alterations in urine of PCa patients due its noninvasive collection, but the analysis of prostate tissue metabolome is an ideal approach to disclose specific modifications in PCa development. This review aims to summarize and discuss the most recent findings from tissue and urine metabolomic studies applied to PCa biomarker discovery. Eighteen metabolites were found consistently altered in PCa tissue among different studies, including alanine, arginine, uracil, glutamate, fumarate, and citrate. Urine metabolomic studies also showed consistency in the dysregulation of 15 metabolites and, interestingly, alterations in the levels of valine, taurine, leucine and citrate were found in common between urine and tissue studies. These findings unveil that the impact of PCa development in human metabolome may offer a promising strategy to find novel biomarkers for PCa diagnosis.MDPIRepositório Institucional da Universidade Fernando PessoaLima, Ana RitaPinto, JoanaAmaro, FilipaBastos, Maria de LourdesCarvalho, MárciaGuedes de Pinho, Paula2021-06-30T09:22:41Z2021-01-01T00:00:00Z2021-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10284/9975engLima, A.R.; Pinto, J.; Amaro, F.; Bastos, M.d.L.; Carvalho, M.; Guedes de Pinho, P. Advances and Perspectives in Prostate Cancer Biomarker Discovery in the Last 5 Years through Tissue and Urine Metabolomics. Metabolites 2021, 11, 181. https://doi.org/10.3390/ metabo110301812218-198910.3390/metabo11030181info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2022-09-06T02:09:16Zoai:bdigital.ufp.pt:10284/9975Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T15:46:45.312763Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Advances and perspectives in prostate cancer biomarker discovery in the last 5 years through tissue and urine metabolomics |
title |
Advances and perspectives in prostate cancer biomarker discovery in the last 5 years through tissue and urine metabolomics |
spellingShingle |
Advances and perspectives in prostate cancer biomarker discovery in the last 5 years through tissue and urine metabolomics Lima, Ana Rita Metabolomics Volatilomics Lipidomics Prostate cancer Biomarkers Metabolic pathways |
title_short |
Advances and perspectives in prostate cancer biomarker discovery in the last 5 years through tissue and urine metabolomics |
title_full |
Advances and perspectives in prostate cancer biomarker discovery in the last 5 years through tissue and urine metabolomics |
title_fullStr |
Advances and perspectives in prostate cancer biomarker discovery in the last 5 years through tissue and urine metabolomics |
title_full_unstemmed |
Advances and perspectives in prostate cancer biomarker discovery in the last 5 years through tissue and urine metabolomics |
title_sort |
Advances and perspectives in prostate cancer biomarker discovery in the last 5 years through tissue and urine metabolomics |
author |
Lima, Ana Rita |
author_facet |
Lima, Ana Rita Pinto, Joana Amaro, Filipa Bastos, Maria de Lourdes Carvalho, Márcia Guedes de Pinho, Paula |
author_role |
author |
author2 |
Pinto, Joana Amaro, Filipa Bastos, Maria de Lourdes Carvalho, Márcia Guedes de Pinho, Paula |
author2_role |
author author author author author |
dc.contributor.none.fl_str_mv |
Repositório Institucional da Universidade Fernando Pessoa |
dc.contributor.author.fl_str_mv |
Lima, Ana Rita Pinto, Joana Amaro, Filipa Bastos, Maria de Lourdes Carvalho, Márcia Guedes de Pinho, Paula |
dc.subject.por.fl_str_mv |
Metabolomics Volatilomics Lipidomics Prostate cancer Biomarkers Metabolic pathways |
topic |
Metabolomics Volatilomics Lipidomics Prostate cancer Biomarkers Metabolic pathways |
description |
Prostate cancer (PCa) is the second most diagnosed cancer in men worldwide. For its screening, serum prostate specific antigen (PSA) test has been largely performed over the past decade, despite its lack of accuracy and inability to distinguish indolent from aggressive disease. Metabolomics has been widely applied in cancer biomarker discovery due to the well-known metabolic reprogramming characteristic of cancer cells. Most of the metabolomic studies have reported alterations in urine of PCa patients due its noninvasive collection, but the analysis of prostate tissue metabolome is an ideal approach to disclose specific modifications in PCa development. This review aims to summarize and discuss the most recent findings from tissue and urine metabolomic studies applied to PCa biomarker discovery. Eighteen metabolites were found consistently altered in PCa tissue among different studies, including alanine, arginine, uracil, glutamate, fumarate, and citrate. Urine metabolomic studies also showed consistency in the dysregulation of 15 metabolites and, interestingly, alterations in the levels of valine, taurine, leucine and citrate were found in common between urine and tissue studies. These findings unveil that the impact of PCa development in human metabolome may offer a promising strategy to find novel biomarkers for PCa diagnosis. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-06-30T09:22:41Z 2021-01-01T00:00:00Z 2021-01-01T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10284/9975 |
url |
http://hdl.handle.net/10284/9975 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Lima, A.R.; Pinto, J.; Amaro, F.; Bastos, M.d.L.; Carvalho, M.; Guedes de Pinho, P. Advances and Perspectives in Prostate Cancer Biomarker Discovery in the Last 5 Years through Tissue and Urine Metabolomics. Metabolites 2021, 11, 181. https://doi.org/10.3390/ metabo11030181 2218-1989 10.3390/metabo11030181 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
MDPI |
publisher.none.fl_str_mv |
MDPI |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799130333798465536 |